Stifel analyst Chris O’Cull maintains McDonald’s (NYSE:MCD) with a Hold and raises the price target from $260 to $270.
Instil Bio Partners with Cell Therapy Leader for ITIL-306 Program, Eyeing Breakthrough in Lung Cancer Treatment
Instil Bio, Inc. ("Instil" or the "Company") (NASDAQ:TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of
